Related Experiment Video
Updated: May 19, 2026

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
Published on: May 12, 2019
Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question
Abstract:
Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product's use.
More Related Videos
11:06Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
Published on: November 11, 2022
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Related Concept Videos
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Prodrugs
Prodrugs help overcome...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Intrauterine Drug Delivery Systems
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices